America’s restaurants face a dilemma: How to sell food in the GLP-1 era
Restaurants are adapting menus for customers using GLP-1 weight-loss medications, which reduce appetite. McDonald's (MCD) and Burger King (QSR) are testing smaller, protein-rich options, while Shake Shack (SHAK) introduced a 'Good Fit' menu. Rising food and labor costs, along with reduced spending by diners, are challenging profitability, with one-third of restaurants reporting losses in 2026. Restaurateurs are exploring creative solutions to balance demand and costs.
How this was made
The 30-second read
Why it matters
It suggests restaurants are experimenting with menu formats (protein emphasis, smaller portions, smaller plates) while grappling with ingredient cost inflation and pricing power.
Market read
For restaurant stocks, the actionable takeaway is management’s evolving stance on GLP-1-driven demand risk and the direction of menu experimentation, not a quantified financial impact.
What to watch
The article emphasizes portion size and protein, but does not quantify how much of the check-size decline is driven by broader affordability pressures (labor, food inflation) versus GLP-1-specific behavior.
Background
The article frames GLP-1 weight-loss drugs as changing restaurant consumption patterns, including fewer full meals, smaller leftovers, and lower average check sizes.
Ticker impact
McDonald’s CEO says the chain has not seen GLP-1 effects yet, but it is testing new menu items like a salad with McCrispy chicken strips.
Likely limited upside or downside as investors weigh “no impact yet” against the need for menu adaptation.
The article provides a fresh management stance plus specific menu tests, but it does not quantify financial impact or provide a decision to launch items.
Restaurant Brands International flags weight-loss medications as a business risk, while Burger King tests smaller portions such as Whopper Bites.
Likely modest negative bias if investors interpret smaller portions as margin-dilutive, offset by potential demand stabilization.
The piece links GLP-1 usage to a stated filing risk and to operational testing, but offers no results or guidance changes.
Shake Shack introduced a “Good Fit” menu emphasizing protein grams and smaller-bun formats, aimed at diners seeking higher protein.
Likely neutral to slightly positive as investors view menu innovation as responsive, without evidence of financial traction.
The article describes the menu concept and pricing parity, but does not disclose adoption, sales lift, or margin effects.
Market effects
Highlights a potential demand and mix shift for restaurant operators toward higher-protein offerings and smaller portions, with margin pressure from ingredient costs and pricing constraints.
Primarily US consumer behavior and restaurant traffic dynamics; limited direct regional differentiation in the article.
Mostly US-focused, but references smaller-plate approaches in Europe as a possible model for menu adaptation.
Counterpoint
GLP-1 adoption may not translate into sustained traffic declines for all chains if menu changes preserve value perception and protein-focused items broaden appeal beyond weight-loss users.
Key entities
- companyMcDonald’s
Testing new menu items while stating it has not yet seen GLP-1 effects on customer behavior.
- companyRestaurant Brands International
Lists weight-loss medications as a risk and notes Burger King is testing smaller portions.
- companyShake Shack
Launched a “Good Fit” menu emphasizing protein grams and smaller-bun formats.
